In one paragraphArticle in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Valeria Torralba-AguConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Investigaciones Farmacológicas (ININFA), Universidad de Buenos Aires, Buenos Aires, Argentina.ORCID https://orcid.org/0009-0003-6186-2835 Natalia FernándezConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Investigaciones Farmacológicas (ININFA), Universidad de Buenos Aires, Buenos Aires, Argentina.ORCID https://orcid.org/0000-0002-8099-6471 Carina ShayoLaboratorio de Patología y Farmacología Molecular, Instituto de Biología y Medicina Experimental, CONICET, Buenos Aires, Argentina.
Carlos DavioConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Investigaciones Farmacológicas (ININFA), Universidad de Buenos Aires, Buenos Aires, Argentina.
C Daniel ZappiaConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Investigaciones Farmacológicas (ININFA), Universidad de Buenos Aires, Buenos Aires, Argentina.ORCID https://orcid.org/0000-0003-3844-577X Federico MonczorConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Investigaciones Farmacológicas (ININFA), Universidad de Buenos Aires, Buenos Aires, Argentina.ORCID https://orcid.org/0000-0002-1113-4608 Funding
Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación PICT2016-2612Universidad de Buenos Aires UBACYT-20020190100015BA
6 · The paper itselfAbstract
This study investigates the impact of histamine H
Indexed as
Leukemia, Myeloid, AcuteReceptor Cross-TalkReceptors, GlucocorticoidReceptors, Histamine H2Cell Line, TumorCell ProliferationCytarabineDexamethasoneDrug Resistance, NeoplasmGlucocorticoidsHistamine AgonistsHumansSignal TransductionCytarabineDexamethasoneGlucocorticoidsHistamine AgonistsReceptors, GlucocorticoidReceptors, Histamine H2cell signalingglucocorticoidshistamineleukemic cell proliferationleukemic cell resistancereceptor crosstalk
Identifiers
PMID42736631
PMCPMC13575286
What OpenQuestion holds
Textmetadata
Read underepoch 390